Phase 1/2 Trial of Durvalumab and Lenalidomide in Patients with Cutaneous T Cell Lymphoma (CTCL): Preliminary Results of Phase I Results and Correlative Studies

• Published in: Blood Vol. 132; no. Supplement 1; p. 2931
• Main Authors: Querfeld, Christiane, Zain, Jasmine M., Wakefield, Devin L., Jovanovic-Talisman, Tijana, Kil, Sung Hee, Estephan, Renee, Sanchez, James, Palmer, Joycelynne, Rosen, Steven T
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 29.11.2018

Background: In CTCL, intratumoral T cells are functionally exhausted and are characterized by the expression of immune inhibitory molecules such as PD1 and PD-L1 (Cancer Immunol Res 6; 2018). These findings justify the evaluation of immune checkpoint inhibition to reverse T cell exhaustion in CTCL....